Ratings by Craig-Hallum (Albert Lowe)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/29/2026 | Rezolute | RZLT | Upgrade | Buy (Hold) |
4.18 (3.58) |
-14.35% | Details | |
| 9/22/2026 | Compass Therapeutics | CMPX | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Buy (N/A) |
34.57 (31.73) |
-8.22% | Details | |
| 6/3/2026 | Cardiff Oncology | CRDF | Downgrade | Hold (Buy) |
1.51 (0.90) |
-40.4% | Details | |
| 5/15/2026 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2026 | Cardiff Oncology | CRDF | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2026 | SAB Biotherapeutics | SABS | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Rezolute | RZLT | Maintain | Hold (N/A) |
|
Details | ||
| 2/12/2026 | Atossa Genetics | ATOS | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Atossa Genetics | ATOS | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | Rezolute | RZLT | Downgrade | Hold (Buy) |
10.94 (4.18) |
-61.79% | Details | |
| 12/4/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
91.91 (120.30) |
30.89% | Details | |
| 11/14/2025 | Actuate Therapeutics | ACTU | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 10/6/2025 | Skye Bioscience | SKYE | Downgrade | Hold (Buy) |
4.75 (1.55) |
-67.37% | Details | |
| 10/2/2025 | Eupraxia Pharmaceuticals | EPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/25/2025 | Echelon | ELON | New Coverage | Buy (N/A) |
11.97 (21.88) |
82.79% | Details | |
| 6/17/2025 | Neurogene | NGNE | New Coverage | Buy (N/A) |
18.97 (23.25) |
22.56% | Details | |
| 6/5/2025 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
0.86 (2.91) |
238.37% | Details | |
| 6/2/2025 | Actuate Therapeutics | ACTU | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2025 | Actuate Therapeutics | ACTU | New Coverage | Buy (N/A) |
8.37 (0.61) |
-92.71% | Details | |
| 4/1/2025 | SAB Biotherapeutics | SABS | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2025 | Skye Bioscience | SKYE | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2025 | Lineage Cell Therapeutics Inc. | LCTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2025 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Buy (N/A) |
3.55 (6.62) |
86.48% | Details | |
| 10/9/2024 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
2.67 (2.53) |
-5.24% | Details | |
| 9/6/2024 | Cardiff Oncology | CRDF | New Coverage | Buy (N/A) |
2.21 (1.51) |
-31.67% | Details | |
| 8/26/2024 | Skye Bioscience | SKYE | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2024 | Lineage Cell Therapeutics Inc. | LCTX | New Coverage | Buy (N/A) |
0.88 (0.98) |
11.36% | Details | |
| 7/9/2024 | Skye Bioscience | SKYE | New Coverage | Buy (N/A) |
6.15 (4.75) |
-22.76% | Details | |
| 5/13/2024 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Buy (N/A) |
2.04 (1.21) |
-40.69% | Details |
